NextStep Robotics, a US-based medical device manufacturer based on research at several Maryland institutions, has raised $750,000 in funding from investors including the Maryland Momentum Fund.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) groupto initiate clinical trial startup activities. In the planned clinical trial, HOVON researchers will evaluate GlycoMimetics’ drug candidate, GMI-1271, in adults with newly diagnosed acute myeloid leukemia (AML) but who cannot tolerate intensive chemotherapy, as well as in patients with myelodysplastic syndrome (MDS) with a high risk of leukemia. The HOVON Central Office has already approved a protocol concept, and this agreement enables HOVON to commit staff to the planned trial in order to finalize the protocol, start regulatory and ethics reviews, and begin development of the database. Separately, GlycoMimetics said it plans to announce the design details for its company-sponsored Phase 3 trial in relapsed/refractory AML patients as part of its fourth-quarter and year-end 2017 earnings call scheduled for March 6, 2018.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin®) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
eNeura, a Baltimore-based company that makes a device to treat migraines, closed a Series D investment round.
When: Tuesday, February 13, 2018 from 5:00 PM to 7:00 PM EST
Where: Bar Louie 150 Gibbs St Rockville, MD 20850
Join BioBuzz and sponsor BioIT Solutions in Rockville at Bar Louie on February 13th, 2018 from 5 – 7pm. Only a 5 minute walk from the Rockville Metro, please join us for this exciting event. BioIT Solutions offers a range of services from enterprise systems built on their 1Platform4® Suite for advanced computational, workflow, and data management systems to IT strategy, architecture and management consulting. The 1Platform4® Suite consists of a software foundation on which various highly configurable modules are assembled and tailored to each client’s specifications and needs.
Orgenesis Inc., (OTCQB:ORGS), a service and research company in the field of the regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products, today announced it has entered into an agreement with Adva Biotechnology Ltd., an innovator of enhanced bioprocessing solutions, for the development of an automated culturing system for use in the provision of contract manufacturing services, as well as Orgenesis’s therapeutic development. This system has the potential to enable cost-efficient and automated manufacturing for autologous cell therapies.
On Sunday, Feb. 25, 2018, the Organization for Rare Diseases India (ORDI), is holding simultaneous walks or races in Bengaluru, Mumbai, and Washington, D.C.
Dovetailing off our Top 27 Venture Players report, we’ve put together the 19 largest AEC and real estate venture rounds of the past year. There were plenty of surprises.
Imagine instead of a pill, a doctor prescribes a game for a child with attention deficit disorder. Or imagine patients dealing with substance abuse being prescribed assessments they can do via a mobile device to track progress.
The University System of Maryland (USM) has selected NextStep Robotics, a start-up company that has developed a personalized robotic therapy to help relieve discomforts of “foot drop” syndrome in recovering stroke patients. The robotic therapy is based on research in the University of Maryland, Baltimore (UMB) School of Medicine, Baltimore Veterans (VA) Affairs Medical Center, and University of Maryland, College Park (UMCP) A. James Clark College of Engineering, as recipient of the second investment from the recently established Maryland Momentum Fund.